ATE511392T1 - Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit - Google Patents

Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit

Info

Publication number
ATE511392T1
ATE511392T1 AT08727550T AT08727550T ATE511392T1 AT E511392 T1 ATE511392 T1 AT E511392T1 AT 08727550 T AT08727550 T AT 08727550T AT 08727550 T AT08727550 T AT 08727550T AT E511392 T1 ATE511392 T1 AT E511392T1
Authority
AT
Austria
Prior art keywords
dosage forms
baclofen
methods
oral dosage
prodrug
Prior art date
Application number
AT08727550T
Other languages
English (en)
Inventor
David Kidney
Kenneth Cundy
Srikonda Sastry
Manshiu Leung
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Application granted granted Critical
Publication of ATE511392T1 publication Critical patent/ATE511392T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08727550T 2007-01-11 2008-01-10 Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit ATE511392T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88459807P 2007-01-11 2007-01-11
PCT/US2008/050796 WO2008086492A1 (en) 2007-01-11 2008-01-10 Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment

Publications (1)

Publication Number Publication Date
ATE511392T1 true ATE511392T1 (de) 2011-06-15

Family

ID=39432550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08727550T ATE511392T1 (de) 2007-01-11 2008-01-10 Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit

Country Status (8)

Country Link
US (1) US20080206332A1 (de)
EP (1) EP2117517B1 (de)
JP (1) JP2010515754A (de)
AT (1) ATE511392T1 (de)
CA (1) CA2674610C (de)
ES (1) ES2365574T3 (de)
TW (1) TWI369982B (de)
WO (1) WO2008086492A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060119971A (ko) * 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
EP1811986B1 (de) 2004-11-04 2014-03-26 XenoPort, Inc. Orale darreichungsformen von gabapentin-prodrug mit verzögerter freisetzung
WO2009061934A1 (en) * 2007-11-06 2009-05-14 Xenoport, Inc. Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
EP2065038A1 (de) 2007-11-30 2009-06-03 Pharnext Neue therapeutische Ansätze zur Behandlung der Charcot-Marie-Tooth Krankheit
PL2378883T3 (pl) * 2008-12-04 2016-06-30 Intec Pharma Ltd SYSTEM DOSTARCZANIA LEKU ZATRZYMYWANEGO W ŻOŁĄDKU dLA ZALEPLONU
CA2753057C (en) 2009-03-03 2018-09-11 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
JP2012524065A (ja) * 2009-04-17 2012-10-11 ゼノポート，インコーポレーテッド ＧＡＢＡＢ受容体リガンドとしてのγ−アミノ酪酸誘導体
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (de) 2009-06-02 2010-12-22 Pharnext Neue Zusammensetzungen zur Behandlung von CMT und verwandten Erkrankungen
US8673340B2 (en) 2009-09-10 2014-03-18 Boston Foundation For Sight Sodium channel blocker delivery system with scleral lens
MX350056B (es) 2009-11-03 2017-08-25 Lupin Ltd Formulacion de liberacion modificada de lacosamida.
WO2011079074A1 (en) * 2009-12-24 2011-06-30 Acura Phamaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
CA2790164A1 (en) * 2010-02-17 2011-08-25 Sun Pharma Advanced Research Company Ltd. Method of treating a disease condition susceptible to baclofen therapy
WO2011101863A2 (en) * 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
WO2011109403A1 (en) 2010-03-01 2011-09-09 Xenoport, Inc. Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence
EP2468261A1 (de) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid
JP6027539B2 (ja) * 2010-12-02 2016-11-16 ウーツェーベー ファルマ ゲーエムベーハーＵｃｂ Ｐｈａｒｍａ Ｇｍｂｈ ラコサミドの１日１回投与用製剤
SI2560631T1 (sl) 2011-03-01 2014-06-30 Pharnext Na baklofenu in akamprosatu temeljeäśa terapija nevroloĺ kih nepravilnosti
EP2705842A1 (de) 2012-09-05 2014-03-12 Pharnext Therapeutische Ansätze zur Behandlung von Morbus Parkinson
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
WO2013023155A1 (en) 2011-08-11 2013-02-14 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use
US9180108B2 (en) 2011-10-27 2015-11-10 Medtronic, Inc. Baclofen formulations and methods for making same
WO2013180796A1 (en) * 2012-06-01 2013-12-05 Lynn Health Science Institute, Inc. Methods for treating insomnia
EP2874617B1 (de) 2012-07-18 2019-02-27 Pharnext Auf baclofen und acamprosat basierende therapie von erkrankungen mit makular degeneration
EP2705841A1 (de) 2012-09-05 2014-03-12 Pharnext Kombinierungen aus Nootropikagenten zur Behandlung von kognitiven Dysfunktionen
EP2705843A1 (de) 2012-09-05 2014-03-12 Pharnext Therapeutische Ansätze zur Behandlung von Epilepsie und zugehöriger Erkrankungen durch Reduzierung der Epileptogenese
WO2014145195A1 (en) 2013-03-15 2014-09-18 Cerovene, Inc. Pharmaceuticals comprising a ph-dependent component and ph-raising agent
SMT201800534T1 (it) 2013-06-05 2019-01-11 Pharnext Soluzioni orali stabili per principi attivi farmaceutici combinati
WO2015121218A1 (en) 2014-02-11 2015-08-20 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
WO2016132217A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Method of improving gaba-b receptor agonist therapy
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
EP3397253A1 (de) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit krämpfen
JP7027318B2 (ja) 2016-02-05 2022-03-01 ファーネクスト 神経障害の新規の併用療法
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
CN111050761A (zh) 2017-04-24 2020-04-21 法奈克斯公司 阿尔茨海默病的基于idalopirdine的组合治疗
SG11202003452XA (en) 2017-10-20 2020-05-28 Eagle Res Labs Limited Dantrolene prodrugs and methods of their use
JP2021512174A (ja) 2018-01-29 2021-05-13 ファーネクストＰｈａｒｎｅｘｔ アセチルコリンエステラーゼ阻害剤療法に対する反応性を失った患者におけるアルツハイマー病のバクロフェン及びアカンプロセートを用いた療法
EP3760190B1 (de) 2019-07-03 2023-05-24 Alvogen, Inc. Tabletten mit kontrollierter freisetzung von pregabalin, verfahren zu ihrer herstellung und verfahren zu ihrer verwendung

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US5006560A (en) * 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
GB9308430D0 (en) * 1993-04-23 1993-06-09 Glaxo Group Ltd Medicaments
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
AU2002211863A1 (en) * 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
JP2005527466A (ja) * 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプトＢインドール誘導体
US6927036B2 (en) * 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
MXPA05010515A (es) * 2003-03-31 2006-03-10 Xenoport Inc Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
US7662987B2 (en) * 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
KR20110097942A (ko) * 2003-08-20 2011-08-31 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
KR20060119971A (ko) * 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
WO2005027850A2 (en) * 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
MXPA06004088A (es) * 2003-10-14 2006-06-27 Xenoport Inc Forma cristalina de un analogo del acido gamma-aminobutirico.
ES2405329T3 (es) * 2003-12-30 2013-05-30 Xenoport, Inc. Síntesis de profármacos de carbarnato de aciloxialquilo y productos intermedios de los mismos
BRPI0509399A (pt) * 2004-04-02 2007-09-18 Impax Laboratories Inc forma de dosagem farmacêutica
EP1811986B1 (de) * 2004-11-04 2014-03-26 XenoPort, Inc. Orale darreichungsformen von gabapentin-prodrug mit verzögerter freisetzung
WO2008011016A2 (en) * 2006-07-18 2008-01-24 Dynogen Pharmaceuticals, Inc. Treating gastroesophageal reflux disease with 5-ht3- and gaba receptor agonists
CA2669246A1 (en) * 2006-11-14 2008-05-22 Xenoport, Inc. Use of gabapentin and pregabalin prodrugs for treating tinnitus
BRPI0720252A2 (pt) * 2006-12-08 2014-01-07 Xenoport Inc Uso de pró-fármacos de análogos de gaba para tratar doenças

Also Published As

Publication number Publication date
JP2010515754A (ja) 2010-05-13
CA2674610C (en) 2013-06-18
WO2008086492A1 (en) 2008-07-17
EP2117517B1 (de) 2011-06-01
CA2674610A1 (en) 2008-07-17
US20080206332A1 (en) 2008-08-28
ES2365574T3 (es) 2011-10-07
TWI369982B (en) 2012-08-11
EP2117517A1 (de) 2009-11-18
TW200900054A (en) 2009-01-01

Similar Documents

Publication Publication Date Title
TWI369982B (en) Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
CY1121593T1 (el) Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
MX374396B (es) Rocio de fentanilo sublingual.
EA201170249A1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
EA201490949A1 (ru) Ингибиторы киназ
CY1114139T1 (el) Πλακιδιο βουπρενορφινης για τη θεραπεια υποκαταστασης ναρκωτικων
MX347106B (es) Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
NO20076508L (no) Acyloksykarbamat prodroger av traneksaminsyre og fremgangsmater for fremstilling og anvendelse derav
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
CY1115381T1 (el) Διενυδρη υδροχλωρικη ναλμεφαινη
WO2011056240A3 (en) Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EA200970483A1 (ru) Применение пролекарств габапентина и прегабалина для лечения шума в ушах
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
CY1112770T1 (el) Αναστολεις κινασης και μεθοδοι χρησης τους
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties